Works Cited

1. Centers for Disease Control and Prevention. The History of Malaria: An Ancient Disease. Available at https://stacks.cdc.gov/view/cdc/135582. Last accessed October 13, 2025.

2. World Health Organization. World Malaria Report: 2024. Geneva: WHO Press; 2025. Available at https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2024. Last accessed October 13, 2025.

3. Centers for Disease Control and Prevention. Malaria. Available at https://www.cdc.gov/malaria. Last accessed October 13, 2025.

4. Centers for Disease Control and Prevention. Clinical Guidance: Malaria Diagnosis and Treatment in the U.S. Available at https://www.cdc.gov/malaria/hcp/clinical-guidance. Last accessed October 13, 2025.

5. Griffith KS, Lewis LS, Mali S, Parise ME. Treatment of malaria in the United States: a systematic review. JAMA. 2007;297(20):2264-2277.

6. Kantele A, Jokiranta S. Plasmodium knowlesi: the fifth species causing human malaria. Duodecim. 2010;126(4):427-434.

7. Wilairatanal P, Krudsood S, Tangpukdee N. Management of Plasmodium knowlesi malaria without PCR confirmation. Southeast Asian J Trop Med Public Health. 2010;41(1):19-21.

8. Lee KS, Cox-Singh J, Singh B. Morphological features and differential counts of Plasmodium knowlesi parasites in naturally acquired human infections. Malar J. 2009;8:73.

9. Cox-Singh J, Davis TM, Lee KS, et al. Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening.Clin Infect Dis. 2008;46(2):165-171.

10. National Institute of Allergy and Infectious Diseases. Malaria. Available at https://www.niaid.nih.gov/diseases-conditions/malaria. Last accessed October 13, 2025.

11. Spadafora C, Awandare GA, Kopydlowski KM, et al. Complement receptor 1 is a sialic acid-independent erythrocyte receptor of Plasmodium falciparum. PloS Pathog. 2010;6(6):e1000968.

12. Figtree M, Lee R, Bain L, et al. Plasmodium knowlesi in human, Indonesian Borneo. Emerg Infect Dis. 2010;16(4):672-674.

13. Zhang M, Fennell C, Ranford-Cartwright L, et al. The Plasmodium eukaryotic initiation factor-2{alpha} kinase IK2 controls the latency of sporozoites in the mosquito salivary glands. J Exp Med. 2010;207(7):1465-1474.

14. Sullivan D. Uncertainty in mapping malaria epidemiology: implications for control. Epidemiol Rev. 2010;32(1):175-187.

15. Mace KE, Lucchi NW, Tan KR. Malaria surveillance—United States, 2018. MMWR. 2022;71(SS8):1-29.

16. Kappe SH, Vaughan AM, Boddey JA, Cowman AF. That was then but this is now: malaria research in the time of an eradication agenda. Science. 2010;328(5980):862-866.

17. Filler SJ, MacArthur JR, Parise M, et al. Locally acquired mosquito-transmitted malaria: a guide for investigations in the United States. MMWR. 2006;55(RR13):1-9.

18. World Health Organization. Malaria. Available at https://www.who.int/news-room/fact-sheets/detail/malaria. Last accessed October 13, 2025.

19. Medicines for Malaria Venture. First Malaria Medicine for Newborn Babies and Young Infants 2–5 kg Receives Approval. Available at https://www.mmv.org/newsroom/news-resources-search/first-malaria-medicine-newborn-babies-and-young-infants-2-5-kg. Last accessed October 13, 2025.

20. Thwing J, Skarbinski J, Newman RD, et al. Appendix: microscopic procedures for diagnosing malaria. MMWR. 2007;56(SS6):39-40.

21. Maltha J, Gillet P, Bottieau E, Cnops L, van Esbroeck M, Jacobs J. Evaluation of a rapid diagnostic test (CareStartTM Malaria HRP-2/pLDH (Pf/pan) Combo Test) for the diagnosis of malaria in a reference setting. Malar J. 2010;9:171.

22. Centers for Disease Control and Prevention. Malaria Diagnostic Tests. Available at https://www.cdc.gov/malaria/hcp/diagnosis-testing/malaria-diagnostic-tests.html. Last accessed October 13, 2025.

23. Centers for Disease Control and Prevention. National Notifiable Disease Surveillance System Malaria (Plasmodium spp.) 2014 Case Definition. Available at https://ndc.services.cdc.gov/case-definitions/malaria-2014/. Last accessed October 13, 2025.

24. Centers for Disease Control and Prevention. How to Report a Case of Malaria. Available at https://www.cdc.gov/malaria/php/case-reporting. Last accessed October 13, 2025.

25. Lucumi E, Darling C, Jo H, et al. Discovery of potent small molecule inhibitors of multi-drug resistant P. falciparum using a novel miniaturized high-throughput luciferase-based assay. Antimicrob Agents Chemother. 2010;54(9):3597-3604.

26. Singh B. Plasmodium knowlesi: an update. Microbiology Australia. 2016;1:39-42.

27. World Health Organization. Malaria: Rapid Diagnostic Tests. Available at https://www.who.int/teams/global-malaria-programme/case-management/diagnosis/rapid-diagnostic-tests. Last accessed October 13, 2025.

28. Centers for Disease Control and Prevention. Appendix C: How to Acquire IV Artesunate in the United States. Available at https://www.cdc.gov/malaria/hcp/clinical-guidance/iv-artesunate-us.html. Last accessed October 13, 2025.

29. World Health Organization. International Travel and Health: Malaria. Available at https://cdn.who.int/media/docs/default-source/travel-and-health/9789241580472-eng-chapter-7.pdf?sfvrsn=8be7067_13. Last accessed October 13, 2025.

30. Centers for Disease Control and Prevention. Travelers' Health: Yellow Book Homepage. Available at https://www.cdc.gov/yellow-book/index.html. Last accessed October 13, 2025.

31. LexiDrug. Available at https://online.lexi.com. Last accessed October 13, 2025.

32. Centers for Disease Control and Prevention. Preventing Malaria while Traveling. Available at https://www.cdc.gov/malaria/prevention/index.html. Last accessed October 13, 2025.

33. Bell DJ, Lalloo DG. Malaria and travelers. In: Zuckerman JN (ed). Principles and Practice of Travel Medicine. 2nd ed. Oxford: Wiley-Blackwell; 2013: 126-132.

34. Centers for Disease Control and Prevention. Malaria Risk Assessment for Travelers. Available at https://www.cdc.gov/malaria/hcp/risk-assessment. Last accessed October 13, 2025.

35. Brunette GW, Nemhauser JB, Kozarsky PE, et al. (eds). CDC Health Information for International Travel 2020. New York, NY: Oxford University Press; 2020.

36. Centers for Disease Control and Prevention. Counterfeit Medicines. Available at https://wwwnc.cdc.gov/travel/page/counterfeit-medicine. Last accessed October 13, 2025.

37. Centers for Disease Control and Prevention. Strategies for Reducing Malaria's Global Impact. Available at https://www.cdc.gov/malaria/php/public-health-strategy/index.html. Last accessed October 13, 2025.

38. UNICEF. Childhood Diseases. Available at https://www.unicef.org/health/childhood-diseases. Last accessed October 13, 2025.

39. Russell TL, Lwetoijera DW, Maliti D, et al. Impact of promoting longer-lasting insecticide treatment of bed nets upon malaria transmission in a rural Tanzanian setting with pre-existing high coverage of untreated nets. Malar J. 2010;9(1):187.

40. World Health Organization. WHO Publishes Recommendations on Two New Types of Insecticide-Treated Nets. Available at https://www.who.int/news/item/14-03-2023-who-publishes-recommendations-on-two-new-types-of-insecticide-treated-nets. Last accessed October 13, 2025.

41. Smereck J. Malaria in pregnancy: update on emergency management. J Emerg Med. 2011;40(4):393-396.

42. Centers for Disease Control and Prevention. Core Drug-based Malaria Prevention Strategies. Available at https://www.cdc.gov/malaria/php/public-health-strategy/drug-strategies.html. Last accessed October 13, 2025.

43. Kayentao K, Garner P, van Eijk AM, et al. Intermittent preventive therapy for malaria during pregnancy using 2 vs 3 or more doses of sulfadoxine-pyrimethamine and risk of low birth weight in Africa: systematic review and meta-analysis. JAMA. 2013;309(6):594-604.

44. Global Malaria Programme. Indoor Residual Spraying: Use of Indoor Residual Spraying for Scaling Up Global Malaria Control and Elimination. Geneva: World Health Organization; 2006. Available at https://apps.who.int/iris/bitstream/handle/10665/69386/WHO_HTM_MAL_2006.1112_eng.pdf. Last accessed October 13, 2025.

45. Alonso PL, Sacarial J, Aponte JJ, et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet. 2004;364(9443):1411-1420.

46. Fauci AS, Touchette NA, Folkers GK. Emerging infectious diseases: a 10-year perspective from the National Institute of Allergy and Infectious Diseases. Emerging Infect Dis. 2005;11(4):519-525.

47. Centers for Disease Control and Prevention. Choosing a Drug to Prevent Malaria. Available at https://www.cdc.gov/malaria/hcp/drug-malaria. Last accessed October 13, 2025.

48. Olotu A, Fegan G, Wambua J, et al. Seven-year efficacy of RTS,S/AS01 malarial vaccine among young African children. New Eng J Med. 2016;374:2519-2529.

49. Malaria Vaccine Initiative. Vaccines. Available at https://www.malariavaccine.org/rd/vaccines. Last accessed October 13, 2025.

50. Clemens J, Moorthy V. Implementation of RTS,S/AS01 malaria vaccine: the need for further evidence. New Eng J Med. 2016;374:2596-2597.

51. Malaria Vaccine Initiative. Research and Development. Available at https://www.malariavaccine.org/rd. Last accessed October 13, 2025.

52. Centers for Disease Control and Prevention. DPDx: Malaria. Available at https://www.cdc.gov/dpdx/malaria/index.html. Last accessed October 13, 2025.

53. Centers for Disease Control and Prevention. Where Malaria Occurs. Available at https://www.cdc.gov/malaria/data-research. Last accessed October 13, 2025.

54. Centers for Disease Control and Prevention. CDC and Malaria. Available at https://www.cdc.gov/malaria/cdc-malaria. Last accessed October 13, 2025.

55. World Health Organization. International Travel and Health: Malaria: 2015 update. Geneva: World Health Organization; 2015.

56. Malaria Vaccine Initiative. First-Generation Vaccine: RTS,S. Available at https://www.malariavaccine.org/existing-vaccines/rtss. Last accessed October 13, 2025.

57. RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015;386(9988):31-45.

58. World Health Organization. World Malaria Report 2018. Available at https://apps.who.int/iris/bitstream/handle/10665/275867/9789241565653-eng.pdf?ua=1. Last accessed October 13, 2025.

59. Centers for Disease Control and Prevention. Congenital malaria—Nassau County, New York, 2004. MMWR. 2005;54(15):383-384.

60. U.S. Food and Drug Administration. CDC and FDA Continue Efforts to Ensure Timely Access to Front-Line Treatments for Severe Malaria. Available at https://www.fda.gov/media/130925/download. Last accessed October 13, 2025.

61. World Health Organization. WHO Recommends Groundbreaking Malaria Vaccine for Children at Risk. Available at https://www.who.int/news/item/06-10-2021-who-recommends-groundbreaking-malaria-vaccine-for-children-at-risk. Last accessed October 13, 2025.

62. World Health Organization. Malaria Vaccines (RTS,S and R21). Available at https://www.who.int/news-room/questions-and-answers/item/q-a-on-rts-s-malaria-vaccine. Last accessed October 13, 2025.

63. Centers for Disease Control and Prevention. Immigrant and Refugee Health: Malaria Guidance. Available at https://www.cdc.gov/immigrant-refugee-health/hcp/overseas-guidance/malaria-guidance.html. Last accessed October 13, 2025.

64. Centers for Disease Control and Prevention. Malaria Vaccines. Available at https://www.cdc.gov/malaria/php/public-health-strategy/malaria-vaccines.html. Last accessed October 13, 2025.

65. Michel M, Skourtanioti E, Pierini F, et al. Ancient Plasmodium genomes shed light on the history of human malaria. Nature. 2024;631(8019):125-133.

Evidence-Based Practice Recommendations Citations

1. Centers for Disease Control and Prevention. Clinical Guidance: Malaria Diagnosis & Treatment in the U.S. Available at https://www.cdc.gov/malaria/hcp/clinical-guidance/general-treatment.html. Last accessed October 14, 2025.


Copyright © 2025 NetCE, PO Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.